title: Case of complete response to everolimus for metastatic renal cell carcinoma.
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Iwasaki
authors.forename: Wataru
authors.initials: W
authors.lastname: Obara
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Fujioka
mesh_terms: D034841:Abdominal Cavity; D058186:Acute Kidney Injury / Q000139:chemically induced; D000077784:Axitinib; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D000068338:Everolimus; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D007191:Indazoles / Q000008:administration & dosage / Q000009:adverse effects; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy; D008197:Lymph Node Excision / Q000009:adverse effects / Q000379:methods; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D009392:Nephrectomy / Q000379:methods*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D014057:Tomography, X-Ray Computed; D028761:Withholding Treatment
chemical_list: D007093:Imidazoles; D007166:Immunosuppressive Agents; D007191:Indazoles; D016898:Interferon-alpha; D047428:Protein Kinase Inhibitors; D000068338:Everolimus; D000077784:Axitinib; D020123:Sirolimus